76 results
10-Q
2024 Q1
TCBP
TC BioPharm (Holdings) plc
15 May 24
Quarterly report
4:06pm
carries out extensive research and development activities, where it benefits from the United Kingdom’s research and development tax relief and expenditure … pension benefits owed to him. The issued ADSs were based on a price per ADS equal to the closing price of the Company’s ADSs on the Nasdaq Capital
8-K
EX-4.1
TCBP
TC BioPharm (Holdings) plc
8 May 24
TC BioPharm Announces Exercise of Warrants for £3.1 Million Gross Proceeds
8:55am
named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(e) regardless
8-K
EX-10.1
TCBP
TC BioPharm (Holdings) plc
8 May 24
TC BioPharm Announces Exercise of Warrants for £3.1 Million Gross Proceeds
8:55am
company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition
8-K
EX-99.1
TCBP
TC BioPharm (Holdings) plc
6 May 24
TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies
8:32am
benefits to the business combination including CAR development expertise as well as gamma delta and alpha beta T-cells. Our existing expertise in gamma
10-K/A
2023 FY
TCBP
TC BioPharm (Holdings) plc
29 Apr 24
Annual report (amended)
5:23pm
of appointment that set out their respective duties and responsibilities. The non-executive directors do not receive benefits upon termination … and benefits of our directors and senior management;
evaluating the performance of senior management in light of such policies and reporting to the board
10-K
xepohrsgn3ze25402v
1 Apr 24
Annual report
5:11pm
10-K
EX-97.1
hbrls
1 Apr 24
Annual report
5:11pm
8-K
c7wenm103ufc8t usrg
12 Mar 24
Unregistered Sales of Equity Securities
7:30am
6-K
EX-10.3
ivhkc542w8k96af672
21 Dec 23
TC BioPharm Announces Pricing of $3.5 Million Public Offering
5:14pm
6-K
EX-10.1
xxpmap61
21 Dec 23
TC BioPharm Announces Pricing of $3.5 Million Public Offering
5:14pm
6-K
EX-10.4
tqo2iluvwsh 5bni3s1j
21 Dec 23
TC BioPharm Announces Pricing of $3.5 Million Public Offering
5:14pm
6-K
EX-10.2
g4adjaf4 qn2nz45
21 Dec 23
TC BioPharm Announces Pricing of $3.5 Million Public Offering
5:14pm
424B4
g818 a006v2
20 Dec 23
Prospectus supplement with pricing info
6:42pm
F-1/A
EX-10.7
76gdd6owmyk
12 Dec 23
Registration statement (foreign) (amended)
9:34pm
F-1/A
EX-4.20
5hljjh7193l5jwm
12 Dec 23
Registration statement (foreign) (amended)
9:34pm
F-1/A
EX-4.19
qjfptmv1k
12 Dec 23
Registration statement (foreign) (amended)
9:34pm
F-1/A
0pzdsre
12 Dec 23
Registration statement (foreign) (amended)
9:34pm
F-1/A
EX-4.21
cqk34um4ttvheum9d 1y
12 Dec 23
Registration statement (foreign) (amended)
9:34pm
424B3
40o9502c lfh
8 Nov 23
Prospectus supplement
4:05pm
F-3/A
gpyudgdgurmkgvxgs
2 Nov 23
Shelf registration (foreign) (amended)
1:11pm